CO2023015694A2 - Compuestos y métodos dirigidos a la epirregulina - Google Patents

Compuestos y métodos dirigidos a la epirregulina

Info

Publication number
CO2023015694A2
CO2023015694A2 CONC2023/0015694A CO2023015694A CO2023015694A2 CO 2023015694 A2 CO2023015694 A2 CO 2023015694A2 CO 2023015694 A CO2023015694 A CO 2023015694A CO 2023015694 A2 CO2023015694 A2 CO 2023015694A2
Authority
CO
Colombia
Prior art keywords
chronic
epiregulin
compounds
pain
methods targeting
Prior art date
Application number
CONC2023/0015694A
Other languages
English (en)
Inventor
Catherine Brautigam Beidler
Michael Parvin Johnson
Jeffrey Streetman Boyles
Daniel Scott Girard
Shannon Marie Harlan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO2023015694A2 publication Critical patent/CO2023015694A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con anticuerpos de la epirregulina, composiciones que los comprenden, y métodos para elaborar y/o usar los 5 anticuerpos y/o composiciones de estos para trastornos del dolor crónico tales como el dolor de la osteoartritis crónico, o el dolor de la neuropatía periférica diabética crónico, o el dolor lumbar crónico
CONC2023/0015694A 2021-05-21 2023-11-20 Compuestos y métodos dirigidos a la epirregulina CO2023015694A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163191496P 2021-05-21 2021-05-21
PCT/US2022/030058 WO2022246078A1 (en) 2021-05-21 2022-05-19 Compounds and methods targeting epiregulin

Publications (1)

Publication Number Publication Date
CO2023015694A2 true CO2023015694A2 (es) 2023-11-30

Family

ID=82100776

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0015694A CO2023015694A2 (es) 2021-05-21 2023-11-20 Compuestos y métodos dirigidos a la epirregulina

Country Status (16)

Country Link
US (1) US20220372124A1 (es)
EP (1) EP4341288A1 (es)
KR (1) KR20240009488A (es)
CN (1) CN117440968A (es)
AR (1) AR125902A1 (es)
AU (1) AU2022277694A1 (es)
BR (1) BR112023021829A2 (es)
CA (1) CA3218753A1 (es)
CO (1) CO2023015694A2 (es)
CR (1) CR20230538A (es)
DO (1) DOP2023000253A (es)
EC (1) ECSP23087684A (es)
IL (1) IL308533A (es)
PE (1) PE20240416A1 (es)
TW (1) TW202313680A (es)
WO (1) WO2022246078A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4969440B2 (ja) * 2004-04-08 2012-07-04 デビッド， ビー． エイガス， 疼痛治療のためのＥｒｂＢアンタゴニスト
AR085484A1 (es) 2011-04-06 2013-10-02 Lilly Co Eli ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA
MX2015007719A (es) * 2012-12-21 2015-09-07 Sykehuset Sørlandet Hf Terapia dirigida del receptor del factor de crecimiento epidermico (egfr) de trastornos neurologicos y dolor.

Also Published As

Publication number Publication date
IL308533A (en) 2024-01-01
AU2022277694A9 (en) 2023-12-07
DOP2023000253A (es) 2023-12-29
CN117440968A (zh) 2024-01-23
TW202313680A (zh) 2023-04-01
AR125902A1 (es) 2023-08-23
CA3218753A1 (en) 2022-11-24
WO2022246078A1 (en) 2022-11-24
AU2022277694A1 (en) 2023-11-30
EP4341288A1 (en) 2024-03-27
BR112023021829A2 (pt) 2023-12-19
KR20240009488A (ko) 2024-01-22
PE20240416A1 (es) 2024-03-05
US20220372124A1 (en) 2022-11-24
ECSP23087684A (es) 2023-12-29
CR20230538A (es) 2023-12-11

Similar Documents

Publication Publication Date Title
BR112022009679A2 (pt) Receptores de antígeno quimérico cd19 e cd22 e usos dos mesmos
CO2020010465A2 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
PE20210633A1 (es) CONSTRUCTOS DE ARNi PARA INHIBIR LA EXPRESION DE PNPLA3 Y METODOS DE USO DE LOS MISMOS
CL2017003039A1 (es) Anticuerpos que une a los ligandos calidina y des-arg10-calidina del receptor b1 de bradicina, método de producción del anticuerpo, composición farmacéutica que lo contiene y uso para el tratamiento del dolor. (divisional solicitud 2590-2014)
CO2017011958A2 (es) Benzamidas sustituidas y métodos para utilizarlas
MX2020004600A (es) Constructos de oligonucleotidos y usos de estos.
PE20230077A1 (es) Moleculas de union al antigeno multiespecificas dirigidas a ligando de tipo delta 3 (dll3) y sus usos
CL2020001930A1 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas.
CL2018003377A1 (es) Compuestos novedosos para tratar enfermedades parasitarias. (divisional solicitud 201803187)
PE20211225A1 (es) Constructos de arni para inhibir la expresion de pnpla3
ECSP21088111A (es) Analogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida
AR105778A1 (es) Composiciones de materia grasa y métodos para fabricarlas y sus usos
CO2019012475A2 (es) Composiciones y productos de fragancia novedosos con efectos mejoradores del estado de ánimo
CL2021003142A1 (es) Inhibidores de pequeñas moléculas de la cinasa inductora del nf-kb.
CO2022018636A2 (es) Moduladores de il-17a
CL2020002038A1 (es) Oligonucleótidos para modular la expresión de tmem106b.
BR112023020450A2 (pt) Anticorpos anti-cd19 e estruturas car-t
CO2023015694A2 (es) Compuestos y métodos dirigidos a la epirregulina
CL2023001565A1 (es) Inhibidores de enzimas
CL2021003534A1 (es) Profármacos de moduladores del receptor de nmda.
CO2021017142A2 (es) Moduladores del receptor de nmda
CO2021005579A2 (es) Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3